FDA Classifies Drug Response Testers as Class II Medical Devices
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the pharmacogenetic assessment system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get access to cool new medical tech faster. If you make or use these devices, get ready for some updated guidelines that balance safety with easier approval.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients: Easier Access to Pharmacogenetics
The FDA is classifying the pharmacogenetic assessment system into Class II (special controls). The agency says this classification will provide a reasonable assurance of safety and effectiveness and will enhance patients' access to these devices by reducing regulatory burdens.
Device Makers: New Class II Controls
Manufacturers of pharmacogenetic assessment systems will see the device type classified into Class II with special controls that will be codified in regulation. The FDA says this action will provide reasonable assurance of safety and effectiveness and will reduce regulatory burdens.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-16036, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Menopause Test System
The FDA is officially putting menopause test systems into a special safety group called Class II to make sure they work well and are safe. This change helps companies bring better menopause tests to patients faster and with fewer hoops to jump through. If you make or use these tests, expect smoother rules soon, helping everyone get reliable results without extra costs or delays.
Next: 2025-16038, Medical Devices; Immunology and Microbiology Devices; Classification of the Mutation Detection Test for Myeloproliferative Neoplasms
The FDA is officially putting mutation detection tests for certain blood cancers into a safer, middle-level category called Class II. This change helps make sure the tests work well and are safe, while also making it easier and faster for patients to get these important tests. Labs and companies making these tests should get ready for new rules that balance safety with quicker access, saving time and possibly money.